关键词: 类天疱疮, 大疱性, 生物制剂, 奥马珠单抗, 度普利尤单抗, 疗效, 安全性

Abstract: 【Abstract】 Objective To systematically review and analyze the efficacy and safety of omalizumab and dupilumab in the treatment of bullous pemphigoid （BP）. Methods A literature search was conducted in PubMed, the Cochrane Library, EMbase, Web of Science, CBMdisc, CNKI, Wanfang Data, and VIP databases from January 1, 2009 to November 30, 2022, to collect literature on the treatment of BP with omalizumab and dupilumab. Efficacy indicators included the complete remission rate, partial remission rate, recurrence rate, etc., while adverse reactions served as a safety indicator. Results A total of 46 publications were included, involving 141 BP patients （65 receiving omalizumab therapy and 76 receiving dupilumab therapy）. The duration of omalizumab treatment was 11 （5, 16） months; 42 （64.6%） patients achieved complete remission, and 13 （20.0%） achieved partial remission; adverse reactions occurred in 6 （9.2%） patients, and 2 deaths （3.1%） were reported. The duration of dupilumab treatment was 4 （4, 5） months, leading to complete remission in 52 （68.4%） patients, and partial remission in 15 （19.7%）; adverse reactions occurred in 3 （3.9%） patients, and no deaths were reported. Conclusions Both omalizumab and dupilumab demonstrated favorable clinical efficacy and safety. However, more randomized controlled trials are needed to further validate these findings.

Key words: Pemphigoid, bullous, Biological agents, Omalizumab, Dupilumab, Therapeutic effect, Safety